๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

19 recruiting trials

for CRS - Cytokine Release Syndrome

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma NCT07657312Phase 21 site๐Ÿ“ Columbus Naresh Bumma ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome NCT05306080EARLY Phase 11 site๐Ÿ“ Philadelphia University of Pennsylvania ยท Tests: Tadekinig alfa (IL-18BP) Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy NCT05905328Phase 1, Phase 26 sites๐Ÿ“ Orange๐Ÿ“ Augusta๐Ÿ“ Boston CytoAgents, Inc. ยท Tests: CTO1681 10 ยตg, CTO1681 20 ฮผg, CTO1681 30 ฮผg, CTO1681 10 ยตg Run-in / 20 ยตg Treatment, CTO1681 20 ยตg Run-in / 30 ยตg Treatโ€ฆ NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites๐Ÿ“ Ankara๐Ÿ“ Ankara๐Ÿ“ Ankara Health Institutes of Turkey ยท Tests: Talikabtagene Autoleucel A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma NCT07589634Phase 238 sites๐Ÿ“ Goodyear๐Ÿ“ Beverly Hills๐Ÿ“ Irvine Janssen Research & Development, LLC ยท Tests: Ramantamig, Tocilizumab, Placebo CytOSorb TreatMent Of Critically Ill PatientS Registry NCT05146336n/a28 sites๐Ÿ“ Klagenfurt๐Ÿ“ Vienna๐Ÿ“ Aachen CytoSorbents, Inc ยท Tests: CytoSorb A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma NCT07106671Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Siltuximab Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) NCT07609940Phase 45 sites๐Ÿ“ Los Angeles๐Ÿ“ St. Petersburg๐Ÿ“ Baton Rouge Regeneron Pharmaceuticals ยท Tests: Linvoseltamab, Tocilizumab Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab NCT06447376Phase 11 site๐Ÿ“ Cleveland Taylor Brooks ยท Tests: Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin Early Detection of Complications During Immunotherapy for Haematological Malignancy NCT06377059NA1 site๐Ÿ“ Copenhagen O Copenhagen University Hospital, Rigshospitalet ยท Tests: WARD Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma NCT06421675Phase 26 sites๐Ÿ“ Vancouver๐Ÿ“ Victoria๐Ÿ“ Hamilton Ontario Clinical Oncology Group (OCOG) ยท Tests: Elranatamab injection Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study NCT06339177n/a2 sites๐Ÿ“ Bethesda๐Ÿ“ Pittsburgh National Institute of Allergy and Infectious Diseases (NIAIโ€ฆ Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study NCT07169487Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Methylene Blue Immune Modulation by Exosomes in COVID-19 NCT05191381n/a1 site๐Ÿ“ Ulm University of Ulm ยท Tests: Application of exosomes in a whole blood assay Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation NCT06008808Phase 11 site๐Ÿ“ St Louis Washington University School of Medicine ยท Tests: Ruxolitinib, Abatacept Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma NCT05972135Phase 217 sites๐Ÿ“ Tucson๐Ÿ“ Denver๐Ÿ“ Denver SCRI Development Innovations, LLC ยท Tests: Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites๐Ÿ“ Anchorage๐Ÿ“ Clovis๐Ÿ“ Fullerton Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy NCT07390071NA1 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Home Automated Telemanagement (HAT) Patient Unit Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) NCT06684379Phase 1, Phase 23 sites๐Ÿ“ Alcalรก de Henares๐Ÿ“ Fuenlabrada๐Ÿ“ Cรณrdoba PEACHES BIOTECH ยท Tests: Placebo comparator, PRS CK STORM, PRS CK STORM
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy